Know Your Ports - Oncology Nursing News
Dec 21, 2017 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters …
How ctDNA Testing Is Being Used To Diagnose And Monitor Cancer
Dec 18, 2024 · “ctDNA testing looks for small pieces of DNA found in a patient’s blood that comes from cancer cells and tumors,” Grafton explains. “Screening for ctDNA can be used to detect …
T-DXd Improves PFS in HR+, HER2-Low/-Ultralow Metastatic …
Dec 11, 2024 · Treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) demonstrated an improvement in progression-free survival (PFS), compared with treatment of physician’s …
Cannabis Has Drug-Drug Interaction Risks With Certain …
Nov 11, 2024 · Cannabis use may impact the efficacy or side effect profile of patients undergoing active cancer treatment, according to research presented at the Society for Integrative …
Low-Dose Tamoxifen Shows Continued Efficacy in Adjuvant …
Feb 17, 2023 · Tamoxifen, at a dose of 5 mg daily (babytam), continued to show a benefit over placebo in reducing the risk of recurrence from invasive breast cancers and ductal carcinoma …
PD-L1 CPS Score Could Direct Treatment Decisions in Recurrent ...
Apr 1, 2022 · PD-L1 combined positive score (CPS) may serve to predict whether a patient with PD-L1–expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) …
Cosibelimab Approved by FDA for Metastatic, Locally Advanced …
Dec 13, 2024 · Cosibelimab-ipdl (Unloxcyt) has been granted FDA approval to treat adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not …
Acalabrutinib Gets Priority Review for Frontline MCL Treatment
Oct 4, 2024 · The FDA granted a priority review to a supplemental new drug application for acalabrutinib (Calquence) for the frontline treatment of adults with mantle cell lymphoma …
Daratumumab Monotherapy Shows Survival Benefit in Smoldering …
Dec 9, 2024 · Compared with active monitoring, subcutaneous daratumumab (Darzalex Faspro) led to significant progression-free survival (PFS) benefit in patients with intermediate- or high …
Tafasitamab Shows Real-World Efficacy in Relapsed/Refractory …
Dec 10, 2024 · A retrospective medical chart review showcased the real-world effectiveness of tafasitamab-cxix (Monjuvi) use in US patients with relapsed or refractory diffuse large B-cell …